Acelyrin (NASDAQ:SLRN) PT Raised to $18.00 at HC Wainwright

Acelyrin (NASDAQ:SLRNGet Free Report) had its price target raised by stock analysts at HC Wainwright from $16.00 to $18.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 326.54% from the stock’s current price.

Separately, Wells Fargo & Company increased their price target on shares of Acelyrin from $11.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 21st. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.00.

View Our Latest Report on Acelyrin

Acelyrin Stock Performance

Acelyrin stock opened at $4.22 on Wednesday. Acelyrin has a 52 week low of $4.14 and a 52 week high of $29.88. The business’s fifty day moving average is $5.49 and its two-hundred day moving average is $6.91. The firm has a market cap of $417.91 million and a P/E ratio of -1.77.

Acelyrin (NASDAQ:SLRNGet Free Report) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.25. On average, equities research analysts predict that Acelyrin will post -3.89 earnings per share for the current year.

Institutional Trading of Acelyrin

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. grew its position in Acelyrin by 118.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 7,243 shares of the company’s stock valued at $49,000 after acquiring an additional 3,921 shares during the last quarter. Amalgamated Bank purchased a new position in Acelyrin in the third quarter valued at $44,000. New York State Common Retirement Fund raised its position in Acelyrin by 84.4% during the fourth quarter. New York State Common Retirement Fund now owns 13,181 shares of the company’s stock worth $98,000 after acquiring an additional 6,032 shares during the period. Strs Ohio acquired a new stake in shares of Acelyrin in the third quarter valued at about $71,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Acelyrin by 66.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 18,718 shares of the company’s stock valued at $126,000 after buying an additional 7,459 shares in the last quarter. Institutional investors own 87.31% of the company’s stock.

Acelyrin Company Profile

(Get Free Report)

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.

Further Reading

Analyst Recommendations for Acelyrin (NASDAQ:SLRN)

Receive News & Ratings for Acelyrin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acelyrin and related companies with MarketBeat.com's FREE daily email newsletter.